Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 234Breast Neoplasms 234Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 135Colorectal Neoplasms 126Leukemia, Myeloid, Acute 123Lung Neoplasms 109Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 72Sarcoma 71Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 56Lymphoma, Non-Hodgkin 55Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 52Hematologic Neoplasms 52Endometrial Neoplasms 52Urinary Bladder Neoplasms 51Rectal Neoplasms 50

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Granulosa cell tumor of the ovary × 90 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡